FMP
Enter
API Tools
Extras
Elevation Oncology, Inc.
ELEV
NASDAQ
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
0.58 USD
-0.0457 (-7.88%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
